Locations:

Tag: canakinumab

21-HVI-2288859-COVID-19-and-the-heart_650x450

August 18, 2021/COVID-19

Canakinumab for COVID-19 With Cardiac Injury: Early Trial Shapes Strategy for Future Investigation

Three C Study suggests 28-day efficacy window, 600-mg dose

November 3, 2017/Heart, Vascular and Thoracic/Insight & Perspectives

CANTOS: Why It’s a Big Deal — and 5 More Things to Know About It

‘A gateway to...a new range of therapies for atherosclerosis’

September 8, 2017/Heart, Vascular and Thoracic/News & Insights

Dr. Steve Nissen on 3 ESC 2017 Trials That Really Matter (Video)

Beyond the headlines on CANTOS, REVEAL, COMPASS

BackPage 1 of 1Next

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy